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The New England Centenarian Study (NECS) was founded in 1994 as a longitudinal study of
centenarians to determine if centenarians could be a model of healthy human aging. Over
time, the NECS along with other centenarian studies have demonstrated that the majority
of centenarians markedly delay high mortality risk-associated diseases toward the ends
of their lives, but many centenarians have a history of enduring more chronic age-related
diseases for many years, women more so than men. However, the majority of centenari-
ans seem to deal with these chronic diseases more effectively, not experiencing disability
until well into their nineties. Unlike most centenarians who are less than 101 years old,
people who live to the most extreme ages, e.g., 107+ years, are generally living proof of
the compression of morbidity hypothesis. That is, they compress morbidity and disability
to the very ends of their lives. Various studies have also demonstrated a strong familial
component to extreme longevity and now evidence particularly from the NECS is revealing
an increasingly important genetic component to survival to older and older ages beyond
100 years. It appears to us that this genetic component consists of many genetic modifiers
each with modest effects, but as a group they can have a strong influence.
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THE NEW ENGLAND CENTENARIAN STUDY AND
EXCEPTIONAL LONGEVITY
The New England Centenarian Study (NECS)1 was founded in
1994 as a population-based study of all centenarians living within
eight towns in the Boston area with the goal of better under-
standing the bio-psycho-social characteristics of centenarians and
their family members and discovering determinants of excep-
tional longevity and healthy aging (Perls et al., 1999). The study
soon expanded enrollment to include siblings of centenarians and
their offspring from throughout North America, and since 2008
there has been a particular effort to locate and recruit subjects
105 years old and older (what Nobu Hirose of the Japanese Cente-
narian Study has termed “semi-supercentenarians”). In addition
to recruiting long lived individuals, the NECS has also recruited
younger referent subjects from families lacking longevity as well
as spouses of centenarians’ offspring. Between 1994 and 2012,
the study has enrolled more than 1,800 centenarians and 123
supercentenarians (age 110+ years), more than 600 centenarian
offspring and 437 controls. The majority of the NECS centenar-
ians were born between 1880 and 1910 and reached a median
survival of 103 years, thus surviving 30–40 years past the median
survival of their birth year cohort. Birth certificates were avail-
able for only about 30% of the centenarians and therefore US
1http://www.bumc.bu.edu/centenarian
census data from the early 1900s and other techniques were
used for validating date of birth (Young et al., 2010; Andersen
et al., 2012). Typically, 99% of age claims 115 years and older
are false, and therefore in the case of supercentenarians, the
NECS takes extra steps to prove a person’s age including fam-
ily reconstitution and collecting multiple forms of proof that
all must be consistent with one another (Young et al., 2010).
Demographic, health, and family history data, as well as physi-
cal and cognitive function data are collected at least once for the
majority of study subjects and are updated annually for living
subjects. DNA samples have also been collected on the majority of
subjects.
WHAT IS THE CUT OFF AGE FOR EXCEPTIONAL SURVIVAL?
Birth cohort life tables provide an indication of the exceptional
survival of centenarians (Bell and Miller, 2005). Based on the
U.S. Social Security Administration birth cohort life table,2 the
median survival for males born between 1896 and 1905 was 63
and 72 years for females and 1% of males and 5% of females
lived past the age of 95 years. 0.1% of males and 1% of females
lived past the age of 100 (Bell and Miller, 2005). The frequencies
of survivors past the age of 100 decrease by a factor of approx-
imately one half for each additional year of life after 100. Their
2http://www.ssa.gov/oact/NOTES/as120/LifeTables_Tbl_7_1900.html
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life span represents a phenomenon of extreme survival that is very
rare in the population, and much more extreme than the human
longevity examined for example in the Leiden Study of Longevity
(Deelen et al., 2011), in which subjects reached an average sur-
vival of 94 years, or the CHARGE consortium (mean age 81 years;
Walter et al., 2011).
Though still rare, the prevalence of people at age 100 years is
growing. When the NECS began in 1994, the estimated preva-
lence in the US and other developed nations was one centenarian
per 10,000. Now, in 2012, the prevalence has doubled to 1 per
5,000. One explanation for such growth is that at the turn of
the last century, marked improvements were taking place in pub-
lic health, particularly ones which impacted upon neonatal and
maternal mortality. In 1900, infant mortality was 10–30% for the
first year of life depending upon the area of the country and 6–9%
of women died due to complications of childbirth.3 Cleaner water
supplies, plumbing, milk pasteurization, marked socioeconomic
improvements, vaccines, and a major increase in the mean years
of education led to major improvements in survival. Then in the
1930s and 1940s, the introduction of antibiotics (sulfa and peni-
cillin), additional vaccines, safe blood transfusion, and of course
many other medical and non-medical advancements led to marked
further improvements in infant survival and also survival in adult-
hood. Figure 2 in Armstrong et al. (1999), illustrates the dramatic
decline in mortality due to infectious diseases in the United States
from 1900 to 1960. Now, in the last 20 or so years, there has
also been a marked effect upon survival to 100 due to reduced
mortality rates amongst the geriatrics population (Vaupel et al.,
1998).
The result is that with these improvements in our environment,
many more people that might have otherwise died during infancy
have the opportunity to take advantage of their longevity poten-
tial and live to much older age. For example, according to James
Evans of the UK’s Department of Work and Pensions, a 20-year-
old today has a three times greater chance of living to age 100
than when their grandparents were 20 (Evans, 2011). That work
produced Table 1 indicating the probabilities of men and women
from different birth cohorts living to 100.
Kaare Christensen and coauthors provide an even more opti-
mistic picture predicting that 50% of French girls born in 2010
will live to 100 (Christensen et al., 2009). Certainly, a pheno-
type achieved by 50% of the population can not be considered
exceptional. However, such projections assume that these large
proportions of the population have the biological wherewithal
3http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4838a2.htm
Table 1 | Chance of living to age 100 according to birth year and sex
(directly from with permission).
Year of birth Male (%) Female (%)
1931 2.5 5.1
1961 10.5 16.2
1991 19.2 26.4
to survive to 100+ years if given the appropriately facilitative
environment and this really is not known.
As discussed below there is a growing body of evidence indi-
cating that an increasingly greater positive genetic influence is
necessary for survival to age 100 and older ages. Presumably, the
vanishing small proportion of people that is able to reach the ages
in the extreme tail of the population is due to the increasing rarity
of genetic and environmental factor combinations that improve
the odds of such rare survival. Supporting this hypothesis is the
observation that while the percentage of the population made up
of 100 year olds over the past 10 years might still be climbing, the
rate of people living to ages 112+ has remained flat.4 The reason
for this could be that specific and very rare genetic signatures are
necessary to achieve these ages. For younger ages, for example 105–
109 years, the necessary genetic/environmental signatures may be
less rare and not all people who have the potential to achieve these
ages have yet done so, thus we see a continued growth in their
prevalence rate. Once we have a better idea of who is predisposed
and by how much, we will be better able to understand what is
exceptional longevity versus average and perhaps even below aver-
age longevity. Complicating matters however is that signatures are
likely different according to some ethnicities and some specific
environmental exposures and therefore definitions of exception-
ality will vary within these contexts. This complex model of many
common and rare genetic variants with modest effects collectively
having an increasingly strong effect on survival to older and older
ages speaks to the importance of centenarian studies from around
the world working closely with one another to effectively compare
and contrast their findings.
EXCEPTIONAL HEALTH SPAN AND THE COMPRESSION OF
MORBIDITY HYPOTHESIS
Ever since Jim Fries proposed his compression of morbidity
hypothesis, published in the New England Journal of Medicine
in 1980, most researchers in Gerontology believed that in order to
survive to 100 years, one necessarily had to markedly delay both
morbidity and disability toward the end of their life. Then, in 2002
Jesse Evert, collected the data and published findings that less than
20% of centenarians had escaped major age-related diseases by the
time they reached the age of 100 and approximately 45% devel-
oped at least one of these diseases before the age of 65 (Evert et al.,
2003). However, consistent with at least part of Fries’ hypothe-
sis, we also previously noted that despite the presence of diseases,
approximately 90% of centenarians delayed disability until the
mean age of 93 years indicating perhaps greater functional reserve
that enabled these individuals to remain independent for a long
time despite the presence of diseases associated with high risks of
disability and mortality (Hitt et al., 1999).
In the past 7 years, as the NECS emphasized the enrollment of
even older subjects, those 105+ years, we noted much later ages
of onset of age-related diseases. At this point we surmised that
Dr. Fries had underestimated the practical limit of human life
span (e.g., 100 years) and we simply had not looked at old enough
ages to test his hypothesis that age-related diseases and disability
4http://www.mapfre.com/fundacion/html/revistas/gerencia/n111/docs/
Estudio1En.pdf
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were compressed to shorter and shorter periods of time as subjects
approached the limit of life span. Once 100 of our subjects had
reached 110+ years, we analyzed our longitudinal data again and
indeed found that at progressively older and older ages of survival
beyond 100 years, there is a progressive compression of disability
and morbidity such that by the survival age of 110 years, subjects
had compressed age-related diseases into the last 5.2% of their
extremely long lives (compared to 17.9% for controls, 9.4% for
subjects age 100–104 years, and 8.9% for those age 105–109 years;
Andersen et al., 2012). Furthermore, at these most extreme ages,
subjects became much more alike in terms of the types and ages of
onset of age-related diseases. This increased homogeneity at oldest
ages and our genetic findings to-date hold great promise for many
more findings regarding factors that facilitate slower aging and the
delay or escape of age-related diseases.
EVIDENCE FOR A STRONG FAMILIALITY OF EXCEPTIONAL
LONGEVITY
Twin studies have shown that only 20–30% of the overall vari-
ability of living to the mid 80s is attributable to genetic variation
(Herskind et al., 1996), and this result is unfortunately and erro-
neously used to indicate the heritability of exceptional longevity.
Work by the Adventist Health Study indicates that with optimal
health related behaviors (e.g., no tobacco or alcohol use, regu-
lar exercise, vegetarianism, effective management of stress) people
should generally be able to achieve an average life expectancy of
about 86 years (Fraser and Shavlik, 2001). This suggests that the
average genome, in combination with optimal health behaviors,
facilitates an average life span of the late eighties and it would
make sense that the vast majority of why one lives to their six-
ties or seventies versus these later octogenarian years would be
explained by health habit choices. As indicated above though, the
odds of living to the mid-eighties are many folds more common
than living to 100 years or older and it is likely that these twin
studies cannot inform us about the heritability of living to 100.
The NECS has enrolled several 100 families with centenarian
siblings and these data have provided increasingly stronger evi-
dence that exceptional longevity clusters in families (Perls et al.,
1998, 2000). As an example, Figure 1 shows two centenarians and
their siblings enrolled in the NECS who reached remarkable ages.
The rarity of such families with clusters of exceptional longevity
was discussed in (Perls et al., 2000). The exceptionality of familial
longevity in a larger number of NECS sibships relative to Framing-
ham Heart Study sibships was also described in (Sebastiani et al.,
2009) using an objective measure of familial longevity. Less than
1% of all the families in the FHS would meet the exceptionality of
the sibships enrolled in the NECS. Additionally, the NECS has also
shown that siblings of centenarians had between 8 and 17 times
greater chances of living past 100 years compared to individuals
from the same birth year cohort (Perls et al., 2002).
The sex-specific sibling relative risk and the prevalence of cen-
tenarians estimated as 1 centenarian every about 5,000 individuals
in the US population can be used to estimate the heritability of the
liability of living past 100 using formulas in (Wray et al., 2010).
Using the online calculator http://gump.qimr.edu.au/genroc/ the
heritability of liability to longevity ranges between 0.33 (females)
and 0.48 (males). Estimates of relative risk of exceptional longevity
for siblings of semi-supercentenarians and supercentenarians are
needed to have a better understanding of the heritability of living
to extreme ages even greater than 100.
While variability in average life span can be explained by envi-
ronmental factors and genetics, exceptional longevity seems to be
more the resultant of genetics rather than environment. Recently,
the Ashkenazi Jewish Centenarian Study has shown that centenar-
ians in their study do not differ from population controls in major
risk factors such as increased BMI, drinking, or smoking (Raj-
pathak et al., 2011). Although lifetime exposures in centenarians
are difficult to measure in a reliable way, this analysis suggests
that environmental factors have little contribution to extreme
longevity, so that most of the heritability of the trait is likely to
have a genetic basis.
GENETIC INFLUENCE UPON SURVIVAL TO VERY OLD AGES
Per the phenomenon of demographic selection (Vaupel et al., 1979;
Carey and Judge, 2001), we initially hypothesized that centenarians
necessarily lack genetic variants associated with premature mortal-
ity and perhaps additionally also have genetic variants associated
with slower aging and reduced risk for age-related diseases and
subsequent mortality, so-called “longevity enabling genes” (see
Figure 2).
FIGURE 1 | Examples of familial clusters of exceptional longevity. The
small pedigree on the left (A) shows a sibship of three centenarians, with
youngest age at death of 100 years. The pedigree on the right (B) shows a
larger sibship of eight, with two centenarians (ages at death 101 and
106 years), three nonagenarians (ages 91, 93, and 94), and three siblings who
live past the age of 80. Squares and circles represent males and females,
diagonal bars represent deceased subjects. Numbers below nodes are birth
years, last age at contact, and death year. For living subjects, the death year is
not available (NA). Red triangles denote probands enrolled in the New
England Centenarian Study.
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FIGURE 2 | Initial hypothesis on the genetic basis of exceptional longevity.
Since there are many different phenotypic presentations of
survival to 100 years we also expected that many genetic vari-
ants contributed to a complex genetic model for exceptional
longevity. Complicating matters, environmental factors which
can be deleterious (e.g., tobacco use is associated with specific
cancers in some people and not others) and others which can
be health-promoting (e.g., daily aspirin use), will effect survival
risk-associated with a person’s genetic profile.
To be able to discover the complex genetic basis of excep-
tional longevity and dissect the trait into sub-phenotypes that
represent different patterns of exceptional survival, we conducted
a genome-wide association study of exceptional longevity with
801 unrelated centenarians from the NECS (median age at death
104 years) and 914 genetically matched controls from the Illu-
mina control repository and the NECS. The initial version of
the results in Science Express in July 2010 contained errors and
we retracted it (Sebastiani et al., 2011). We published the cor-
rected version in (Sebastiani et al., 2012b) after extensive cleaning
of the data and independent validation of the genotype data.
Analysis of approximately 240,000 single nucleotide polymor-
phisms (SNP) showed that only one SNP in TOMM40/APOE
(rs2075650) reached irrefutable genome-wide significance, while
a large number of SNPs were significantly associated with excep-
tional longevity but did not pass corrections for multiple com-
parisons (p-value for association between 10−2 and 10−7). This
result was consistent with other studies of longevity that failed
to identify genome-wide significant associations beyond APOE
but detected many associated SNPs with more moderate levels
of significance (Newman et al., 2010; Deelen et al., 2011; Walter
et al., 2011). In addition to traditional one-SNP-at-a-time analysis
we introduced a new method to capture the simultaneous effect
of many genetic variants that individually have minor to modest
effects, but as a group assert a substantial influence upon sur-
vival to extreme old age. The method comprised essentially three
steps:
1. The first step builds a set of mathematical models that can
be used together to distinguish centenarians from individuals
selected from the general population using only genetic data.
2. The second step uses the set of models to generate a genetic
risk profile of exceptional longevity for each study subject.
These genetic risk profiles of centenarians can be analyzed
using cluster analysis that essentially groups centenarians based
on different patterns of genetic risk. We termed the average
profiles associated with these clusters as “genetic signatures”
of exceptional longevity and they represent combinations of
genetic variants that produce a similar chance or probability
for exceptional longevity.
3. The third step correlates these genetic signatures with dif-
ferent phenotypic paths to exceptional longevity, to begin to
understand what genetic variants are associated with different
patterns of exceptional longevity.
For step 1, we used a class of Bayesian classification models
that are suitable to analyze case-control studies and developed a
forward search algorithm to build nested models with increasing
numbers of SNPs and a stopping rule based on sensitivity and
specificity of the classification models. To derive the models, all
approximately 240,000 SNPs were ranked according to their pos-
terior probability of association with exceptional longevity, and
SNPs in strong linkage disequilibrium were pruned out (Sebas-
tiani et al., 2012b). Then beginning with the SNP demonstrating
the strongest probability, a set of nested Bayesian classification
models was built by adding one SNP at a time from the sorted list
of SNPs, and the sensitivity (centenarians predicted as centenari-
ans) and specificity (controls predicted as controls) was assessed.
SNPs were no longer added when both the specificity and sensitiv-
ity did not increase significantly. These types of Bayesian models
can be mathematically related to logistic models with a genetic
risk score (Sebastiani et al., 2012c), but they can be adapted more
easily to include multiple traits and additional covariates (Hartley
et al., 2012).
This algorithm identified 281 SNPs in 130 genes and intragenic
regions that include well known aging and age-related disease
genes, but also novel genes. The set of models was used together
to distinguish between centenarians and controls using an aver-
age (ensemble) of the predictions of each single model. It is well
known that an ensemble of prediction models usually outperform
single “best” models because it is more robust to inclusion of false
positive SNPs (Rokach, 2010).
To validate this set of models, we tested their joint accuracy
to distinguish between centenarians and controls in independent
sets of centenarians and controls reaching 60% specificity and a
sensitivity between 58 and 85% (the older the centenarians the
greater the sensitivity). The sensitivity of the set of models to dis-
tinguish controls from nonagenarians and older was low (58%),
but was higher to distinguish controls from older centenarians.
This result is consistent with an increasing genetic contribution to
reach older and older ages beyond 100 years. The lower specificity
could be due to the fact that longevity variants are also present in
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the controls and that other non-genetic factors may be needed to
for individuals to survive to very extreme ages.
In step 2, the set of 281 SNPs and models were used to first
summarize the prediction of the set of nested models in the form
of genetic risk profiles. The display of genetic risk profiles provides
information about the enrichment of longevity variants of an indi-
vidual because subjects with similar genetic profiles share most of
the longevity SNPs and therefore a similar risk for longevity (See
Figure 3). By cluster analysis of the genetic risk profiles, cente-
narians with similar genetic risk profiles can then be grouped to
generate what we called genetic signatures of exceptional longevity.
We used a Bayesian model-based cluster analysis that is described
in (Ramoni et al., 2002) to group centenarians with similar genetic
risk profiles. This approach essentially clusters centenarians with
genetic risk profiles that follow the same probability distribution.
Full details are in (Sebastiani et al., 2012b). We further found
that different genetic signatures correlate with significantly differ-
ent life spans and significantly different ages of onset of major
age-related diseases such as dementia, cancer, and cardiovascu-
lar disease. Note that while a genetic risk profile informs about
the enrichment of risk variants that an individual carries, genetic
signatures represent the prevalent genetic risk profiles that lead
to different risks. Therefore, genetic signatures can be used for
dissection of a complex trait, patient stratification, experimental
design, and understanding the mechanism that links genotype to
phenotype.
THE ROLE OF DISEASE ALLELES AND LONGEVITY
One of our hypotheses about the genetic make-up of exceptional
longevity was that a relative lack of disease-associated variants
could in part explain centenarians’ survival advantage. To test
this hypothesis we computed the rate of SNP alleles that were
associated with a variety of diseases and traits in several GWASs
from the catalog of published genome-wide association studies5
(Hindorff et al., 2009) and the Human Gene Mutation Database
(HGMD; Stenson et al., 2009). We found 1,214 of the 62,339
disease-associated SNPs in the GWAS of exceptional longevity
and we did not observe a significant difference in the rate of
disease-associated variants carried by centenarians and popula-
tion controls. The analysis was conducted by stratifying the rates
by disease type and in none of the 14 groups of disease that we
analyzed did we note a difference between centenarians and a large
number of controls from the NECS and other GWAS. This result
agreed with recent findings from the Leiden Longevity and Leiden
85+ Studies that in their nonagenarian sample, the rate of disease-
associated variants for a select group of age-related diseases was
the same as in the general population (Beekman et al., 2010).
Although this analysis is incomplete because the genotype data
did not include most of the known disease variants and the Illu-
mina controls are likely healthy, we noted an equivalent result in
the whole genomes of two supercentenarians (Sebastiani et al.,
2012a). These two genomes included only 1% of mutations from
the HGMD and approximately 50% of the mutations that were
linked to common diseases in genome-wide association studies.
These disease mutations included known SNPs linked to age-
related diseases such as Alzheimer’s and ALS, cancer and cardiovas-
cular disease. Compared to 11 other whole genome sequences, the
5http://www.genome.gov/26525384
FIGURE 3 | Examples of two similar genetic risk profiles that are highly
predictive of exceptional longevity and a cluster of profiles that include
the two profiles. The x -axis displays the 281 SNPs, sorted by the significance
of the association with exceptional longevity. The y -axis represents the
posterior probability of exceptional longevity given the nested sets of SNPs.
The two genetic risk profiles in the top panel represent the pattern of risk for
varying combinations of genotypes of the 281 SNPs that we found associated
with exceptional longevity. The two plots are not exactly the same, meaning
that the two subjects have some different alleles of the 281 SNPs. However,
the similar pattern of risk means that they essentially have the same genetic
basis for exceptional longevity and were assigned to the same cluster
displayed in the bottom panel.
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FIGURE 4 | Revised hypothesis for the prevalences of disease and longevity (or protective) associated variants with increasing age at very old ages.
two supercentenarian genomes carried a rate of disease variants
comparable to the Venter and Watson genomes and even higher
rates compared to Caucasians from the 1,000 Genomes project.
Realizing that disease-associated variants are not necessarily
weeded out of the population as people survive to the most
extreme ages, we have subsequently revised the hypothesis that
we began our studies with (Figure 2). As shown in Figure 4, we
now hypothesize that with increasing age there is not so much a
decline in the prevalence of disease-associated genetic variants but
rather there is a selection for longevity-associated variants which
not only can counter the deleterious effects of genetic and environ-
mental factors but also afford protection against basic mechanisms
of aging, slow the rate of aging and delay the onset of age-related
diseases, and syndromes.
NOTICEABLE GENES LINKED TO EXCEPTIONAL LONGEVITY
AND FOLLOW UPS
The 281 SNPs that we found predictive of exceptional longevity
include SNPs in genes associated with age-related diseases such as
Alzheimer’s, dementia, and cardiovascular disease. Although the
SNP rs2075650 in TOMM40/APOE reached genome-wide signif-
icance and the AA genotype is associated with increased odds for
exceptional longevity, its effect was limited and we showed that
this SNP explains only 1% of the predictive accuracy of the joint
set of 281 SNPs (Sebastiani et al., 2012b). The GG genotype of this
SNP is linked to the ε4 allele of the APOE gene and while carriers
of this genotype are clearly predisposed to early mortality, carri-
ers of the AA genotype seem to have a small survival advantage
compared to AG carriers (Schupf et al., 2012). We are currently
conducting replication studies of these 281 SNPs to identify the
most robust longevity variants to be carried forward in functional
studies. The centenarians’ genomes that we published in (Sebas-
tiani et al., 2012a) suggest that most of the SNPs in the list of 281
are located closer to coding SNPs compared to randomly cho-
sen SNPs. For example, the two genomes included more than
50% of the longevity variants in genes and approximately 20%
of these mutations were within 10 kb from coding mutations.
These data helped us identify new coding mutations for exam-
ple in the progeria genes LMNA and WRN which is particularly
interesting since these findings suggest that different variations of
these genes may lead to either extreme premature aging or extreme
longevity. Details of the specific mutations are in (Sebastiani et al.,
2012a).
CONCLUSION
People surviving to 100 years and older generally delay the onset
of disability well into their nineties. For those who survive to
the most extreme ages, for example beyond 105 years, we have
observed a progressive compression of morbidity as well. These
oldest of the old individuals also appear to be more phenotypi-
cally homogeneous compared to people surviving to just 100 years.
Numerous genome-wide association studies of centenarians have
yielded only very few statistically significant findings. The most
notable and consistent of these is a variant of apolipoprotein E
which has been shown in candidate gene studies to be the vari-
ant APOE ε4 which is both rare and deleterious in centenarian
studies of various ethnicities. Interestingly though, for some eth-
nicities, the frequency of this allele can be substantially greater.
Analyses of sibships that cluster for exceptional longevity and the
increasing but rare phenotypic homogeneity of the most extreme
old still suggest a strong genetic component. Thus, the NECS and
other studies hypothesize that exceptional longevity is a complex
trait influenced by multiple genetic variants that individually have
modest effects, but as a group can exert a strong effect. Using a
Bayesian analytic approach to construct a genetic model that pre-
dicts exceptional longevity, we have found that with older and
older age beyond 100 years, this genetic influence appears to get
stronger and stronger. While the APOE ε4 allele has garnered much
attention for its negative association with exceptional longevity,
we found that its contribution to distinguishing between cente-
narians and healthy controls is minimal (Sebastiani et al., 2012b).
Also counter to the conventional wisdom, now several studies have
shown that centenarians have many of the disease-associated vari-
ants found in the general population thus suggesting an important
role for protective variants that counter the effects of these dele-
terious variants as well as possibly slow the rate of aging and
the decrease the risk for age-related diseases that contribute to
premature mortality. Genetic models such as these may be used
to discover new target genes and pathways related to aging and
longevity.
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